Wednesday, 12 October 2016

Dabrafenib/Trametinib update Combi v.

Presentation of Caroline Robert (Abstract LBA40):

''In the COMBI-v study of 704 patients with BRAF V600E/K-mutant melanoma, results of an updated 3-year analysis revealed an increased rate of overall survival with first-line dabrafenib
plus trametinib compared with vemurafenib (45% versus 32%, respectively) with no apparent increase in toxicities.

Combination dabrafenib/trametinib   shows also a median overall survival of 26,1 months on combination versus 17, 2 months on vemurafenib.

Combi-v compared dabrafenib/trametinib with vemurafenib alone while Combi d compared the dabrafenib/trametinib with dabrafenib alone. Both trials demonstrated the superiority of combination (see figure bellow), thus combination Dabrafenib /Trametinib  is (highly) recommended as first line therapy in melanoma for Braf positive patients.

Important to start when LDH is still normal and the patient has few metastasis (<3 organ sites metastasis) -in this situation the response is impressive:  70% OS rate at 3 years.

No comments:

Post a Comment